Ultra-Low-Dose Naltrexone (ULDN)

Microgram-range naltrexone taken alongside opioids — used to reduce tolerance, blunt withdrawal, or smooth a Suboxone taper.

⚠️ This post is community information, not medical advice. ULDN is even less mainstream than LDN. Most prescribers haven’t heard of it; published clinical data is sparse outside of pain-medicine contexts. Anything below is a starting point for your own research and for a conversation with a clinician familiar with this approach. If you decide to try it, do so with medical oversight — the dosing is genuinely tricky and the margin for error matters.

ULDN is not the same as LDN. They share a molecule and a name; they differ by three orders of magnitude in dose and by what they’re actually doing. Mixing them up gets you the wrong outcome.

LDN: 1.5 to 4.5 milligrams. Taken after you’re past acute withdrawal, opioid-free, with a 7-to-10-day washout. Goal: PAWS, mood, low-grade misery, post-acute recovery.
ULDN: typically 1 to 100 micrograms (0.001 to 0.1 mg). Taken alongside opioids, including Suboxone. Goal: reduce tolerance, reduce withdrawal severity, or smooth the bottom of a taper.

If you take an LDN-sized dose (mg range) while on opioids, you will precipitate withdrawal. If you take a ULDN-sized dose (μg range) while opioid-free, you will probably feel nothing. The same molecule does different things at different orders of magnitude — that’s the whole premise of this tool.

What it is (general overview)

At ultra-low doses, naltrexone (and the related antagonist naloxone) is proposed to selectively block one mode of opioid-receptor signaling while leaving the other intact. The technical version: mu-opioid receptors can couple to both inhibitory G-proteins (Gi/Go, which mediate analgesia) and excitatory G-proteins (Gs, which mediate tolerance, hyperalgesia, and physical dependence). The model — popularized by Stan Crain and Ke-Fei Shen — is that opioid antagonists have much higher affinity for the Gs-coupled excitatory mode, so vanishingly small doses can block the “tolerance and dependence” side of the receptor without touching the “pain relief” side.

In practice, what this looks like clinically:

Less tolerance buildup when ULDN is combined with an opioid
Less hyperalgesia (the pain-amplifying effect of long-term opioid use)
Less withdrawal severity when the opioid is eventually stopped
Sometimes, enhanced opioid analgesia at the same opioid dose

The proposed mechanism is still debated, and not every study replicates the effect. The clinical signal is strongest in acute pain settings (intraoperative, post-surgical) and in chronic opioid maintenance, where ULDN co-administered with the opioid produced measurable reductions in tolerance progression and withdrawal severity in several trials.

Why people in this community look into it

ULDN comes up in this community for two specific situations:

1. Smoothing the bottom of a Suboxone taper

The last 0.5 to 1 mg of a bupe taper is where most people stall. The half-life is long, the receptor occupancy is still meaningful, and the “final mile” symptoms can drag on for weeks. Some clinicians have used ULDN co-administered with low-dose Suboxone or Subutex during the last stretch of a taper, reportedly to:

Reduce subjective withdrawal severity at each step-down
Reduce the hold-time needed between drops
Make the final drop to zero less brutal

The community signal here is preliminary — small numbers of people, no controlled trials specifically on this protocol. But the underlying pharmacology (blocking the excitatory-signaling side of the bupe-bound receptor) is at least theoretically consistent.

2. Reducing tolerance during longer-term Suboxone or Subutex use

For people on long-term maintenance who notice their bupe dose is slowly creeping up, or who are pre-empting that drift, ULDN added to the regimen has been used as a tolerance-stabilization tool. Same mechanism, different goal: keep the opioid dose flat over time rather than letting tolerance push it upward.

This is not the same as LDN-after-withdrawal. ULDN is with the opioid, not after.

Critical: dose accuracy matters more than with LDN

The dose range for ULDN is on the order of 1 to 100 micrograms — roughly 30 to 3,000 times smaller than LDN. At those scales:

Pill-cutting doesn’t work. You cannot reliably cut a 50 mg naltrexone tablet down to 10 μg by quartering it.
Compounding pharmacies are required, and they need to understand that they’re making a μg-range preparation, not the mg-range LDN they’re more used to. Verify with the pharmacist.
Liquid titration is the standard approach — naltrexone HCl dissolved in a known volume, then a measured fraction taken. This is the same general technique used for the bottom of a Suboxone taper (see #suboxone-custom-dose).
Errors are unforgiving. A 10× dosing mistake puts you into LDN territory and, if you’re on opioids, into precipitated-withdrawal territory.

If you can’t get a compounding pharmacy and a prescriber who both understand μg-range dosing, don’t try to improvise this at home. The math gets out of hand fast and the consequences of overshooting while on opioids are bad.

Practical stuff (general info; your provider’s protocol takes precedence)

Typical reported doses in pain-medicine and ULDN-with-bupe contexts range from about 1 μg to 100 μg per day, often split twice daily. The Crain/Shen ratio used in some studies puts ULDN at roughly 1/10,000 of the opioid dose as a starting estimate, but real protocols vary widely.
Onset: unlike LDN, effects (when present) are reported within days, not weeks. If it’s going to help, it usually helps quickly.
Side effects are generally mild and similar to LDN: occasional vivid dreams, mild GI, headache. The lower the dose, the less you’d expect.
Combination with Suboxone/Subutex: the pharmacology says this should be additive in the right direction (less tolerance, less withdrawal). Real-world experience is consistent with that for most people. A small minority report increased withdrawal-like symptoms, which generally means the dose was too high — drop by 10×, retry.

How to get it

Same general path as LDN, with extra emphasis on the compounding pharmacy understanding what you need:

A prescriber willing to prescribe it off-label. ULDN-aware prescribers are rarer than LDN-aware ones. Pain-medicine doctors and addiction-medicine specialists are the most likely.
A 503A compounding pharmacy that has done μg-range naltrexone preparations specifically. Ask. Some pharmacies that make LDN don’t go below 1 mg.

Telehealth options for ULDN specifically are limited. Some LDN telehealth platforms will consider μg dosing on request, but it’s case by case. Most people who use ULDN in this community got there via their own prescriber rather than a turnkey telehealth service.

What ULDN is not

Not a replacement for MAT. It’s an adjunct during MAT, not a substitute.
Not for use after washout. That’s LDN. If you’re past withdrawal and looking for a PAWS tool, LDN is the page for you.
Not a substitute for a real taper plan. ULDN may smooth the bottom of a taper; it doesn’t replace the taper.
Not well-validated for the specific use cases above. The pharmacology is plausible, the small-trial evidence is encouraging in pain-medicine contexts, but large-scale data for “ULDN-with-bupe during taper” specifically doesn’t exist. You’d be running an N-of-1 experiment, and that’s worth being honest about.
Not appropriate without medical oversight. The dose accuracy required, the interaction with whatever opioid you’re on, and the potential to overshoot into LDN territory all make this a tool that needs a prescriber in the loop.